IRF8 and breast cancer: Among these patients, the IRF8 promoter was hypermethylated in 49.12% (56/114) of breast cancer tissues (Figure 3A and Table 1) and 16.67% (2/12) of surgical-margin tissues (Figure 3B and Table 1).